Analysts await Codexis, Inc. (NASDAQ:CDXS) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $-0.15 EPS, down 20% or $0.03 from last year’s $-0.12 per share.

At the moment 4 analysts are watching Codexis, Inc. (NASDAQ:CDXS), 0 rate it “Buy”, 3 “Outperform”, 1 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 4 analysts have a mean sales target of 9.45 million. For the quarter ending Sep-16, 4 analysts have a mean sales target of 9.48 million whilst for the year ending Dec-16, 4 analysts have a mean target of 47.55 million.

In terms of earnings per share, 4 analysts have a -0.09 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 4 analysts have a -0.10 EPS mean target and for the quarter ending Sep-16 there are 4 estimates of -0.17 EPS.

The biggest institutional shareholders in Codexis, Inc. include Vivo Ventures VII LLC which owns 6 million shares in the company valued at $19.67 million. Nantahala Capital Management, LLC is the second biggest holder with 5 million shares currently valued at 20.35 million whilst Opaleye Management Inc has 2 million shares valued at 6.77 million.

Total shares held by institutions as of the most recent company filings are 19,751,438 with a reported 1,129,898 bought and 479,214 sold. These holdings make up 48.8% of the company’s outstanding shares.

Currently insiders hold 3,399,584 shares in the business which makes up 8.40% of shares. The biggest holder currently is John J. Nicols who owns 999,157 shares (2.47% of those outstanding), whilst Dr. Patrick Y. Yang, PhD holds 290,246 (0.72% of shares outstanding) and Mr. Douglas T. Sheehy holds 247,617 (0.61% of shares outstanding).

The stock decreased 0.62% or $0.02 during the last trading session, hitting $5.49. Codexis, Inc. (NASDAQ:CDXS) has risen 35.34% over the past 6 months and is uptrending.